[go: up one dir, main page]

CL2008003551A1 - Uso de fosfato y fumarato de propionato de 3-(2,2,2-trimetilhidrazinio) en la preparacion de medicamentos utiles en la profilaxis y el tratamiento de aterosclerosis. - Google Patents

Uso de fosfato y fumarato de propionato de 3-(2,2,2-trimetilhidrazinio) en la preparacion de medicamentos utiles en la profilaxis y el tratamiento de aterosclerosis.

Info

Publication number
CL2008003551A1
CL2008003551A1 CL2008003551A CL2008003551A CL2008003551A1 CL 2008003551 A1 CL2008003551 A1 CL 2008003551A1 CL 2008003551 A CL2008003551 A CL 2008003551A CL 2008003551 A CL2008003551 A CL 2008003551A CL 2008003551 A1 CL2008003551 A1 CL 2008003551A1
Authority
CL
Chile
Prior art keywords
trimethylhydrazinium
prophylaxis
atherosclerosis
treatment
fumarate
Prior art date
Application number
CL2008003551A
Other languages
English (en)
Inventor
Stonans Ilmars
Original Assignee
Joint Sotock Company Grindeks
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40481525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008003551(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Joint Sotock Company Grindeks filed Critical Joint Sotock Company Grindeks
Publication of CL2008003551A1 publication Critical patent/CL2008003551A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Uso de las sales de propionato de 3-(2,2,2-trimetilhidrazinio) para el tratamiento y/o profilaxis de la aterosclerosis.
CL2008003551A 2007-12-04 2008-11-28 Uso de fosfato y fumarato de propionato de 3-(2,2,2-trimetilhidrazinio) en la preparacion de medicamentos utiles en la profilaxis y el tratamiento de aterosclerosis. CL2008003551A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07122273 2007-12-04
EP07122272 2007-12-04

Publications (1)

Publication Number Publication Date
CL2008003551A1 true CL2008003551A1 (es) 2010-01-22

Family

ID=40481525

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003551A CL2008003551A1 (es) 2007-12-04 2008-11-28 Uso de fosfato y fumarato de propionato de 3-(2,2,2-trimetilhidrazinio) en la preparacion de medicamentos utiles en la profilaxis y el tratamiento de aterosclerosis.

Country Status (32)

Country Link
US (1) US20100234459A1 (es)
EP (1) EP2222293B1 (es)
JP (1) JP2011505408A (es)
KR (1) KR20100084688A (es)
CN (1) CN101951898B (es)
AR (1) AR069521A1 (es)
AT (1) ATE518536T1 (es)
AU (1) AU2008333262A1 (es)
BR (1) BRPI0819057A2 (es)
CA (1) CA2706354C (es)
CL (1) CL2008003551A1 (es)
CO (1) CO6280477A2 (es)
CY (1) CY1112336T1 (es)
DK (1) DK2222293T3 (es)
DO (1) DOP2010000163A (es)
EA (1) EA019424B1 (es)
GE (1) GEP20125673B (es)
HR (1) HRP20110744T1 (es)
IL (1) IL205961A0 (es)
MA (1) MA31993B1 (es)
MX (1) MX2010006255A (es)
MY (1) MY150508A (es)
PA (1) PA8805901A1 (es)
PE (1) PE20091037A1 (es)
PL (1) PL2222293T3 (es)
PT (1) PT2222293E (es)
RS (1) RS51992B (es)
SI (1) SI2222293T1 (es)
TN (1) TN2010000250A1 (es)
TW (1) TW200930356A (es)
WO (1) WO2009071585A1 (es)
ZA (1) ZA201003641B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2425835A1 (en) * 2010-08-18 2012-03-07 Grindeks, a joint stock company A new medical use of 3-(2,2,2-trimethylhydrazinium) propionate dihydrate and natural flavonoid derivatives
TWI487524B (zh) * 2010-12-03 2015-06-11 Tetra Sia 菸鹼酸和米曲肼之新穎治療組合

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1667960T3 (da) * 2003-08-04 2008-06-09 Grindeks Jsc Meldoniumsalte, fremgangsmåde til deres fremstilling og farmaceutisk sammensætning på deres basis

Also Published As

Publication number Publication date
KR20100084688A (ko) 2010-07-27
TW200930356A (en) 2009-07-16
TN2010000250A1 (en) 2011-11-11
AU2008333262A1 (en) 2009-06-11
CO6280477A2 (es) 2011-05-20
BRPI0819057A2 (pt) 2015-05-05
IL205961A0 (en) 2010-11-30
CA2706354A1 (en) 2009-06-11
WO2009071585A1 (en) 2009-06-11
PL2222293T3 (pl) 2012-01-31
EP2222293A1 (en) 2010-09-01
MY150508A (en) 2014-01-30
MX2010006255A (es) 2011-03-15
EA201000738A1 (ru) 2011-04-29
PT2222293E (pt) 2011-11-15
HRP20110744T1 (hr) 2011-11-30
DK2222293T3 (da) 2011-11-21
CN101951898B (zh) 2012-12-05
PA8805901A1 (es) 2009-07-23
CA2706354C (en) 2013-08-13
US20100234459A1 (en) 2010-09-16
ZA201003641B (en) 2011-03-30
ATE518536T1 (de) 2011-08-15
MA31993B1 (fr) 2011-01-03
RS51992B (sr) 2012-04-30
DOP2010000163A (es) 2010-08-31
EP2222293B1 (en) 2011-08-03
JP2011505408A (ja) 2011-02-24
SI2222293T1 (sl) 2011-12-30
CY1112336T1 (el) 2015-12-09
PE20091037A1 (es) 2009-08-19
GEP20125673B (en) 2012-10-25
EA019424B1 (ru) 2014-03-31
CN101951898A (zh) 2011-01-19
AR069521A1 (es) 2010-01-27

Similar Documents

Publication Publication Date Title
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
NO20081878L (no) Diacylindazolderivater som lipase- og fosfolipaseinhibitorer
CR20110608A (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
MX349796B (es) Composiciones farmacéuticas para usarse en el tratamiento de trastornos oncológicos mediante el uso de coenzima q10.
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
CL2008003088A1 (es) Metodo de preparacion de la sal de de maleato de (e)-n-{4-[3-cloro-4-(2-piridinilmetoxi)anilino]-3-ciano-7-etoxi-6-quinolinil}-4-(dimetilanino)-2-butenamida; formas cristalinas anhidra y monohidrato de la sal maleato; metodo de preparacion; composicion farmaceutica; utiles en el tratamiento de cancer.
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
CL2007002100A1 (es) Compuestos derivados biciclicos que contienen nitrogeno, sus sales, solvatos y n-oxidos; composicion farmaceutica; y uso para el tratamiento de infecciones bacterianas.
UY32649A (es) "sales de 4-(dimetilamino)butil 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato"
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
BRPI0911203A2 (pt) peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo.
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
PT2054045E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento da artrite e da dor
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
AR094241A1 (es) Ciclesonida para el tratamiento de la enfermedad de las vias respiratorias en caballos
NO20080133L (no) Azolopyridin-2-on derivater som lipase og fosfolipaseinhibitorer
CR10255A (es) "nuevas composiciones terapéuticas para el tratamiento o la prevención de trastornos psicóticos"
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
NO20080035L (no) Benzooksazol-2-on derivater som lipase og fosfolipaseinhibitorer